Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer, Phase III study finds

Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer(NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.

​Medical Xpress – latest medical and health news stories

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *